Levormeloxifene
Levormeloxifene (L-Centchroman) is a selective estrogen receptor modulator (SERM), which prevents and ameliorates postmenopausal osteoporosis. Levormeloxifene causes multiple adverse gynecological effects.
For research use only. We do not sell to patients.
- CAS No.: 78994-23-7
- Formula: C30H35NO3
- Molecular Weight:457.60
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Ishikawa | EC50 |
13 nM
Compound: 4 (Levormeloxifene)
|
Stimulation of alkaline phosphatase activity in Ishikawa human endometrial adenocarcinoma cells
Stimulation of alkaline phosphatase activity in Ishikawa human endometrial adenocarcinoma cells
|
[PMID: 11738564] |
Chemical Information
-
CAS No. 78994-23-7
-
Molecular Weight 457.60
-
Formula C30H35NO3
-
SMILES
CC1([C@H]([C@@H](C2=CC=C(C=C2O1)OC)C3=CC=C(C=C3)OCCN4CCCC4)C5=CC=CC=C5)C
-
Synonyms
L-Centchroman; L-Ormeloxifene
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Levormeloxifene Related Classifications
HY-122359 Related Classifications
Powered by Bioz